Literature DB >> 2820136

Inhibition of poliovirus uncoating by disoxaril (WIN 51711).

H Zeichhardt, M J Otto, M A McKinlay, P Willingmann, K O Habermehl.   

Abstract

Disoxaril [WIN 51711, 5-[7-[4(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3- methylisoxazole] inhibits the replication of polioviruses types 1 and 2 in HeLa cells by stabilizing the virus capsid, which results in the inhibition of the pH-dependent viral uncoating in endosomes and/or lysosomes. As shown by electron microscopy the virus entered into the cell by receptor-mediated endocytosis via coated pits and coated vesicles into endosomes irrespective of the presence or absence of the compound. Measurements of viral RNA synthesis showed that disoxaril completely inhibited the arrival of viral RNA in the cytoplasm for new RNA synthesis only when the inocula were preincubated with disoxaril for 15 min at 37 degrees at 0.3 microgram disoxaril/ml for poliovirus type 1 and 0.03 microgram disoxaril/ml for poliovirus type 2. Simultaneous addition of the compound and virus resulted in reduced inhibition of viral RNA synthesis. The inhibitory effect of the compound could be partially reversed up to 25 min p.i. if the compound was eluted from the cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820136     DOI: 10.1016/0042-6822(87)90075-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures.

Authors:  A W Dove; V R Racaniello
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Hijacking the endocytic machinery by microbial pathogens.

Authors:  Ann En-Ju Lin; Julian Andrew Guttman
Journal:  Protoplasma       Date:  2010-06-25       Impact factor: 3.356

3.  Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.

Authors:  M P Fox; M A McKinlay; G D Diana; F J Dutko
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  Lack of myristoylation of poliovirus capsid polypeptide VP0 prevents the formation of virions or results in the assembly of noninfectious virus particles.

Authors:  D Marc; G Masson; M Girard; S van der Werf
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

5.  Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA.

Authors:  K Kirkegaard
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Cold-adapted poliovirus mutants bypass a postentry replication block.

Authors:  A W Dove; V R Racaniello
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

7.  The pentamer channel stiffening model for drug action on human rhinovirus HRV-1A.

Authors:  N Vaidehi; W A Goddard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.

Authors:  B A Heinz; R R Rueckert; D A Shepard; F J Dutko; M A McKinlay; M Fancher; M G Rossmann; J Badger; T J Smith
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

9.  Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.

Authors:  Daniel C Pevear; Frederick G Hayden; Tina M Demenczuk; Linda R Barone; Mark A McKinlay; Marc S Collett
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

10.  In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.

Authors:  M G Woods; G D Diana; M C Rogge; M J Otto; F J Dutko; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.